InfuSystem Holdings, Inc. (NYSE:INFU – Get Free Report) Director Kenneth D. Eichenbaum acquired 4,000 shares of the company’s stock in a transaction dated Monday, September 23rd. The shares were purchased at an average price of $5.89 per share, with a total value of $23,560.00. Following the completion of the acquisition, the director now owns 4,000 shares in the company, valued at $23,560. The purchase was disclosed in a filing with the SEC, which is available at this link.
InfuSystem Stock Up 2.9 %
Shares of NYSE INFU opened at $6.75 on Friday. The company has a quick ratio of 1.64, a current ratio of 2.07 and a debt-to-equity ratio of 0.64. InfuSystem Holdings, Inc. has a 1-year low of $5.74 and a 1-year high of $10.99. The stock has a market capitalization of $143.74 million, a PE ratio of -675,000.00 and a beta of 1.46.
InfuSystem (NYSE:INFU – Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.01). InfuSystem had a net margin of 0.28% and a return on equity of 0.70%. The firm had revenue of $33.70 million during the quarter.
Institutional Investors Weigh In On InfuSystem
Analysts Set New Price Targets
INFU has been the topic of several research reports. B. Riley assumed coverage on shares of InfuSystem in a report on Thursday. They issued a “buy” rating and a $13.00 price target on the stock. StockNews.com lowered shares of InfuSystem from a “strong-buy” rating to a “buy” rating in a research report on Saturday.
View Our Latest Report on INFU
InfuSystem Company Profile
InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.
See Also
- Five stocks we like better than InfuSystem
- How Technical Indicators Can Help You Find Oversold StocksĀ
- Can Costco Stock Hit New Highs as Interest Rates Drop?
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- These 3 Stocks Show How to Navigate Declining Consumer Confidence
- EV Stocks and How to Profit from Them
- MicroStrategy’s Returns Are 3X Higher Than Bitcoin: Time to Buy?
Receive News & Ratings for InfuSystem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InfuSystem and related companies with MarketBeat.com's FREE daily email newsletter.